Monitoring molecular response by BCR-ABL, JH and WT-1 in Ph+ ALL treated with imatinib containing regimen

Preliminary report of two cases

Maurizio Miglino, R. Varaldo, N. Colombo, R. Grasso, M. Clavio, A. Garuti, S. Aquino, A. Albarello, M. Sessarego, M. Gobbi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

We carried out sequential molecular monitoring of different markers on two BCR-ABL positive ALL patients receiving a standard dose induction regimen, which was followed by a maintenance therapy that alternated imatinib and chemotherapy administration. Molecular study was performed at diagnosis, at the end of the induction phase, and then every three months during maintenance therapy. Each marrow sample underwent BCR-ABL analysis (p210 and p 190 expression by RT-PCR and Real-time PCR) and monoclonal JH rearrangement analysis, while WT1 gene expression was detected by Real-time PCR. At diagnosis we detected high WT1 expression associated with the presence of both BCR-ABL transcripts and monoclonal JH rearrangement in both patients. Hematological remission, as well as a molecular status characterized by undetectable BCR-ABL expression, normal levels of WT1 expression, and persistence of monoclonal JH rearrangement, were achieved by both patients post-therapy. Follow up of patient 1 showed a progressive increase in WT-1 and in p-190 transcript, which was followed by cytogenetic and hematological relapse. We observed a progressive increase in the p210 transcript without a concomitant increase in WT-1 levels in patient 2. JH rearrangement was detected in all the samples analyzed. The molecular results may indicate the persistence of JH rearranged clonal cells with undetectable BCR-ABL. From a clinical point of view, our preliminary experience suggests that simultaneous analysis of BCR-ABL, JH and WT-1 expression may improve the study of MRD in Ph+ ALL.

Original languageEnglish
Pages (from-to)321-324
Number of pages4
JournalJournal of Experimental and Clinical Cancer Research
Volume25
Issue number3
Publication statusPublished - Sep 2006

Fingerprint

Real-Time Polymerase Chain Reaction
Cytogenetics
Therapeutics
Bone Marrow
Imatinib Mesylate
Gene Expression
Recurrence
Drug Therapy
Polymerase Chain Reaction

Keywords

  • BCR-ABL
  • Imatinib
  • Ph+ALL
  • WT-1. JH

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Monitoring molecular response by BCR-ABL, JH and WT-1 in Ph+ ALL treated with imatinib containing regimen : Preliminary report of two cases. / Miglino, Maurizio; Varaldo, R.; Colombo, N.; Grasso, R.; Clavio, M.; Garuti, A.; Aquino, S.; Albarello, A.; Sessarego, M.; Gobbi, M.

In: Journal of Experimental and Clinical Cancer Research, Vol. 25, No. 3, 09.2006, p. 321-324.

Research output: Contribution to journalArticle

@article{643d3c8654694213b1faa49ac8f8e219,
title = "Monitoring molecular response by BCR-ABL, JH and WT-1 in Ph+ ALL treated with imatinib containing regimen: Preliminary report of two cases",
abstract = "We carried out sequential molecular monitoring of different markers on two BCR-ABL positive ALL patients receiving a standard dose induction regimen, which was followed by a maintenance therapy that alternated imatinib and chemotherapy administration. Molecular study was performed at diagnosis, at the end of the induction phase, and then every three months during maintenance therapy. Each marrow sample underwent BCR-ABL analysis (p210 and p 190 expression by RT-PCR and Real-time PCR) and monoclonal JH rearrangement analysis, while WT1 gene expression was detected by Real-time PCR. At diagnosis we detected high WT1 expression associated with the presence of both BCR-ABL transcripts and monoclonal JH rearrangement in both patients. Hematological remission, as well as a molecular status characterized by undetectable BCR-ABL expression, normal levels of WT1 expression, and persistence of monoclonal JH rearrangement, were achieved by both patients post-therapy. Follow up of patient 1 showed a progressive increase in WT-1 and in p-190 transcript, which was followed by cytogenetic and hematological relapse. We observed a progressive increase in the p210 transcript without a concomitant increase in WT-1 levels in patient 2. JH rearrangement was detected in all the samples analyzed. The molecular results may indicate the persistence of JH rearranged clonal cells with undetectable BCR-ABL. From a clinical point of view, our preliminary experience suggests that simultaneous analysis of BCR-ABL, JH and WT-1 expression may improve the study of MRD in Ph+ ALL.",
keywords = "BCR-ABL, Imatinib, Ph+ALL, WT-1. JH",
author = "Maurizio Miglino and R. Varaldo and N. Colombo and R. Grasso and M. Clavio and A. Garuti and S. Aquino and A. Albarello and M. Sessarego and M. Gobbi",
year = "2006",
month = "9",
language = "English",
volume = "25",
pages = "321--324",
journal = "Journal of Experimental and Clinical Cancer Research",
issn = "0392-9078",
publisher = "BioMed Central Ltd.",
number = "3",

}

TY - JOUR

T1 - Monitoring molecular response by BCR-ABL, JH and WT-1 in Ph+ ALL treated with imatinib containing regimen

T2 - Preliminary report of two cases

AU - Miglino, Maurizio

AU - Varaldo, R.

AU - Colombo, N.

AU - Grasso, R.

AU - Clavio, M.

AU - Garuti, A.

AU - Aquino, S.

AU - Albarello, A.

AU - Sessarego, M.

AU - Gobbi, M.

PY - 2006/9

Y1 - 2006/9

N2 - We carried out sequential molecular monitoring of different markers on two BCR-ABL positive ALL patients receiving a standard dose induction regimen, which was followed by a maintenance therapy that alternated imatinib and chemotherapy administration. Molecular study was performed at diagnosis, at the end of the induction phase, and then every three months during maintenance therapy. Each marrow sample underwent BCR-ABL analysis (p210 and p 190 expression by RT-PCR and Real-time PCR) and monoclonal JH rearrangement analysis, while WT1 gene expression was detected by Real-time PCR. At diagnosis we detected high WT1 expression associated with the presence of both BCR-ABL transcripts and monoclonal JH rearrangement in both patients. Hematological remission, as well as a molecular status characterized by undetectable BCR-ABL expression, normal levels of WT1 expression, and persistence of monoclonal JH rearrangement, were achieved by both patients post-therapy. Follow up of patient 1 showed a progressive increase in WT-1 and in p-190 transcript, which was followed by cytogenetic and hematological relapse. We observed a progressive increase in the p210 transcript without a concomitant increase in WT-1 levels in patient 2. JH rearrangement was detected in all the samples analyzed. The molecular results may indicate the persistence of JH rearranged clonal cells with undetectable BCR-ABL. From a clinical point of view, our preliminary experience suggests that simultaneous analysis of BCR-ABL, JH and WT-1 expression may improve the study of MRD in Ph+ ALL.

AB - We carried out sequential molecular monitoring of different markers on two BCR-ABL positive ALL patients receiving a standard dose induction regimen, which was followed by a maintenance therapy that alternated imatinib and chemotherapy administration. Molecular study was performed at diagnosis, at the end of the induction phase, and then every three months during maintenance therapy. Each marrow sample underwent BCR-ABL analysis (p210 and p 190 expression by RT-PCR and Real-time PCR) and monoclonal JH rearrangement analysis, while WT1 gene expression was detected by Real-time PCR. At diagnosis we detected high WT1 expression associated with the presence of both BCR-ABL transcripts and monoclonal JH rearrangement in both patients. Hematological remission, as well as a molecular status characterized by undetectable BCR-ABL expression, normal levels of WT1 expression, and persistence of monoclonal JH rearrangement, were achieved by both patients post-therapy. Follow up of patient 1 showed a progressive increase in WT-1 and in p-190 transcript, which was followed by cytogenetic and hematological relapse. We observed a progressive increase in the p210 transcript without a concomitant increase in WT-1 levels in patient 2. JH rearrangement was detected in all the samples analyzed. The molecular results may indicate the persistence of JH rearranged clonal cells with undetectable BCR-ABL. From a clinical point of view, our preliminary experience suggests that simultaneous analysis of BCR-ABL, JH and WT-1 expression may improve the study of MRD in Ph+ ALL.

KW - BCR-ABL

KW - Imatinib

KW - Ph+ALL

KW - WT-1. JH

UR - http://www.scopus.com/inward/record.url?scp=33751119788&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751119788&partnerID=8YFLogxK

M3 - Article

VL - 25

SP - 321

EP - 324

JO - Journal of Experimental and Clinical Cancer Research

JF - Journal of Experimental and Clinical Cancer Research

SN - 0392-9078

IS - 3

ER -